Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2025)

Amylyx Pharmaceuticals has reported Current Assets over the past 5 years, most recently at $323.7 million for Q4 2025.

  • Quarterly results put Current Assets at $323.7 million for Q4 2025, up 70.86% from a year ago — trailing twelve months through Dec 2025 was $323.7 million (up 70.86% YoY), and the annual figure for FY2025 was $323.7 million, up 70.86%.
  • Current Assets for Q4 2025 was $323.7 million at Amylyx Pharmaceuticals, down from $353.4 million in the prior quarter.
  • Over the last five years, Current Assets for AMLX hit a ceiling of $464.7 million in Q4 2023 and a floor of $105.0 million in Q4 2021.
  • Median Current Assets over the past 5 years was $323.7 million (2025), compared with a mean of $300.5 million.
  • Biggest five-year swings in Current Assets: soared 264.11% in 2022 and later tumbled 59.23% in 2024.
  • Amylyx Pharmaceuticals' Current Assets stood at $105.0 million in 2021, then soared by 264.11% to $382.1 million in 2022, then increased by 21.6% to $464.7 million in 2023, then tumbled by 59.23% to $189.4 million in 2024, then soared by 70.86% to $323.7 million in 2025.
  • The last three reported values for Current Assets were $323.7 million (Q4 2025), $353.4 million (Q3 2025), and $186.9 million (Q2 2025) per Business Quant data.